Replay available

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q2 2025 earnings conference call, held 2025-08-12. Replay captured from the company's public earnings webcast.

Tue, August 12, 2025 at 8:00 AMendedReplay
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Rob Schaller

Chief Financial Officer

Dave Lucci

President and Chief Executive Officer

Jim Malloy

Analyst, Alliance Global Partners

Matthew Keller

Analyst, H2O Network

Replay transcript excerpt

Greetings and welcome to the Accurate Pharmaceuticals to discuss second quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Robert Shaw, Chief Financial Officer. Please go ahead. Thank you, Stacey. Good morning and welcome to our call. This morning we issued a press release providing financial results and company highlights for the second quarter of 2025, which is available on our website at acorexpharma.com. Joining me today is Dave Lucci, President and CEO of Acorex, who will give a corporate update and outlook. Following that, I'll provide some highlights of the financials from the second quarter ended June 30th And then turn the call back over to Dave for his closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements, which are based on current information, assumptions, estimates, and projections about future events that are all subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Investors should consider these risks and other information described in our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed yesterday, Monday, August 11, 2025. You are cautioned not to place undue reliance on these forward-looking statements and after X disclaims any obligation to update such statements at any time in the future. This conference call contains time-...

More from Acurx Pharmaceuticals, Inc.